[ALT] Bacteriophage Therapy

Bacteriophage therapy — using viruses that specifically infect and kill bacteria to treat bacterial infections — was developed a decade before penicillin and practiced widely in the 1920s–30s, then largely abandoned in the West when antibiotics proved simpler to use. The rise of antibiotic-resistant bacteria is making phage therapy urgently relevant again.

The Fork

What won: Antibiotic therapy — penicillin (Fleming 1928, Florey/Chain 1940), streptomycin (Waksman 1943), tetracycline (1948), and hundreds of subsequent antibiotics. Simple, chemically defined, shelf-stable, broad-spectrum, and manufacturable at industrial scale. They transformed medicine almost overnight.

What was abandoned: Phage therapy — Félix d'Hérelle (Institut Pasteur) discovered bacteriophages in 1917 and by the 1920s was using them to treat cholera, dysentery, plague, and typhoid in India, Georgia, and France. The Eliava Institute (Tbilisi, Georgia, 1923, still operational) produced phage preparations for the Soviet military throughout WWII. The West largely abandoned phage therapy after WWII because antibiotics were simpler.

Why Phage Therapy Was Underestimated

The abandonment was partly rational: early phage preparations were inconsistent (varying quality, host range uncertainty) and the mechanism was poorly understood. Antibiotics were chemically defined, reliably dosed, and broad-spectrum. But phage therapy's apparent weaknesses were also strengths:

• Precision targeting: Phages kill only specific bacterial species or strains, leaving the microbiome intact. Broad-spectrum antibiotics kill beneficial bacteria, causing side effects and opportunistic infections (C. difficile).
• Co-evolution: Bacteria that develop phage resistance often lose virulence or become sensitive to antibiotics again (the "evolutionary trap" strategy).
• Self-amplifying: Phages replicate at the infection site — more phages where more bacteria are, fewer where bacteria are eliminated.

The Crisis That Is Reviving It

Antimicrobial resistance (AMR) kills ~1.3 million people per year directly (2019, Lancet); WHO projects 10 million deaths/year by 2050. Many common pathogens (K. pneumoniae, A. baumannii, P. aeruginosa) are now resistant to all antibiotics. Phage therapy is one of the few alternatives.

Recent clinical results: Compassionate use cases in the US (UC San Diego phage therapy centre) and Europe have saved patients with untreatable infections. Phase I/II clinical trials are ongoing (PhagoBurn EU, WRAIR military programme). The Georgian Eliava Institute never stopped — it has treated millions of patients with phage preparations over 100 years.

Current Status

Actively revived — UC San Diego Center for Innovative Phage Applications and Therapeutics (IPATH), AmpliPhi Biosciences (acquired by Armata Pharmaceuticals), Pherecydes Pharma (France), Adaptive Phage Therapeutics, BiomX (Israel). FDA Phase II trials ongoing. EU Framework Programme funding phage research heavily. The Eliava Institute has been rediscovered by Western medicine.

Discovery Character

Surprise level: High — the rediscovery of a pre-antibiotic therapy as a solution to the post-antibiotic crisis is historically ironic. D'Hérelle's work was dismissed by Western medicine for 50 years.

Mode of abandonment: Institutional and economic (antibiotics were patentable, phages were not; antibiotics scaled more easily). Mode of revival: necessity driven by the failure of the dominant paradigm (antibiotic resistance) — a classic Kuhnian crisis.